Streetbeat News

NUMIF

Numinus Wellness Inc.

http://rojoresources.com/

CEO

Allen Morishita

Industry

Testing Laboratories

Open

0.03

Mkt cap

8.7M

Volume

17K

High

0.03

P/E Ratio

-0.45

52-wk high

0.15

Low

0.03

Div yield

N/A

52-wk low

0.02

The Department of Defense Health Agency is funding a trial for PTSD treatment using Seelos Therapeutics' intranasal ketamine, SLS-002. Cybin Inc. reported strong efficacy in its Phase 2 trial of psilocybin derivative CYB003 for Major Depressive Disorder. Clearmind Medicine announced results from a pre-clinical trial combining its MEAI treatment with SciSparc's PEA for various disorders. Clearmind also underwent a reverse stock split to comply with Nasdaq's minimum bid price rule. Beckley Retreats is launching a new psilocybin retreat program, and Mindbloom is introducing a ketamine therapy program. Seelos Therapeutics launched a public offering, and other companies reported financial results or updates. The AdvisorShares Psychedelics ETF and several psychedelics stocks' trading performance are also highlighted.

Portfolio Pulse from Lara Goldstein

December 05, 2023 | 3:12 pm

Numinus Wellness (OTC:NUMIF) reported Q4 and full year fiscal 2023 results, showing a 256.9% year-over-year revenue increase to $23.2 million, largely due to the Novamind acquisition and organic growth. Q4 revenue grew 1.7% to $6.1 million, despite a gross margin decrease to 29.5%. The company reduced its cash burn rate to under $1 million per month and is focusing on profitability. Numinus also partnered with MAPS for MDMA-assisted therapy training and doubled its PAT course cohort.

Portfolio Pulse from The Dales Report

November 30, 2023 | 4:27 pm

The Multidisciplinary Association for Psychedelic Studies (MAPS) and its subsidiary MAPS PBC have published results from a Phase 3 study on MDMA-assisted therapy for PTSD, showing significant reduction in symptoms. The therapy is expected to be considered for FDA approval in 2024. If approved, the DEA would reschedule MDMA for prescription medical use. Numinus Wellness (OTC:NUMIF), a MAPS research partner, has hailed the results as a significant milestone for the healthcare and psychedelic industries.

Portfolio Pulse from Lara Goldstein

September 15, 2023 | 9:14 pm

NY-based consulting firm Research Nester predicts the global market for psychedelic substances will grow at a CAGR of around 14% over the next 12 years, reaching $12 billion by 2035. The report features key players such as COMPASS Pathways, Silo Pharma, Numinus Wellness, Cybin, Mind Medicine, PharmaTher Holdings, atai Life Sciences, Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer. The growth is attributed to increased demand for psychedelic drugs to treat mental health issues, reduced production costs due to the pandemic, and increased investment in R&D.

Portfolio Pulse from Lara Goldstein

September 12, 2023 | 8:35 pm

A bipartisan bill has created a $75 million research grant program for the potential treatment of mental health conditions in active duty military members. The Multidisciplinary Association for Psychedelic Studies (MAPS) announced its final agenda for its upcoming event, which will include information on two recently-identified lead compounds. Psychedelics were featured on Anderson Cooper’s CNN show. Several companies, including Silo Pharma, Clearmind, and SciSparc, are developing treatments using psychedelics. The AdvisorShares Psychedelics ETF (PSIL) showed an uptrend.

Portfolio Pulse from Lara Goldstein

July 03, 2023 | 9:01 pm

Numinus Wellness (OTC:NUMIF) will utilize Optimi Health’s (OTC:OPTHF) GMP-compliant MDMA for a therapist-experiential training program in Canada, supported by MAPS. PharmAla Biotech Holdings (OTC:PMBHF) has received a permit to export its GMP-compliant MDMA LaNeo to the University of Sydney.

Portfolio Pulse from Lara Goldstein

June 20, 2023 | 12:43 pm

Numinus Wellness Inc. (OTC:NUMIF) has partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS) to conduct a Phase 1 clinical study on MDMA-assisted therapy. The trial aims to provide practitioners with unique experiential opportunities, pending approval of their Clinical Trial Application (CTA) by Health Canada.

Portfolio Pulse from The Dales Report

June 16, 2023 | 5:06 pm

Numinus Wellness' Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study on LSD compound MM-120 for General Anxiety Disorder. CCR has enrolled and dosed 19 trial participants and is enrolling volunteers at a second research clinic. Numinus is also a site for COMPASS Pathways' clinical trial of psilocybin therapy for Treatment-Resistant Depression.

Portfolio Pulse from Lara Goldstein

June 05, 2023 | 8:27 pm

MindBio Therapeutics has been granted approval to begin the world's first Phase 2a take-home LSD microdosing trial for Major Depressive Disorder. Cybin Inc. announced the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing Phase 1 trial. Positive long-term follow-up data from Sunstone Therapies’ Phase 2 study assessing COMPASS Pathways’ synthetic psilocybin COMP360 in cancer patients with MDD has been released.

Portfolio Pulse from Lara Goldstein

May 31, 2023 | 3:59 pm

Numinus Wellness' Cedar Clinical Research has joined COMPASS Pathways' Phase 3 program studying psilocybin therapy for Treatment-Resistant Depression (TRD). The trial is part of the largest-ever international clinical program assessing psilocybin therapy, enrolling over 800 participants. Topline data from the Phase 3 clinical program is expected in summer 2024 and mid-2025.

Portfolio Pulse from Lara Goldstein

May 30, 2023 | 8:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.